Investors with an appetite for growth in the biotechnology sector may want to take a closer look at MiMedx Group, Inc. (NASDAQ: MDXG), a company that stands out with an impressive potential upside of 81.36%, according to analyst ratings. MiMedx is making significant strides in the healthcare industry with its innovative placental tissue allografts, which are gaining traction for their applications in wound care, surgical, and burn fields.

Based in Marietta, Georgia, MiMedx Group specializes in developing and distributing placental tissue allografts. These products, including EPIFIX and AMNIOFIX, leverage the company’s proprietary PURION process, which preserves the tissue’s biological properties. This cutting-edge technology…